{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:47:47Z","timestamp":1766767667535},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T00:00:00Z","timestamp":1390867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s11940-013-0282-1","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T01:46:40Z","timestamp":1390787200000},"source":"Crossref","is-referenced-by-count":38,"title":["Diagnosis and Treatment of Corticobasal Degeneration"],"prefix":"10.1007","volume":"16","author":[{"given":"Melissa J.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,28]]},"reference":[{"issue":"11","key":"282_CR1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","volume":"61","author":"DW Dickson","year":"2002","unstructured":"Dickson DW, Bergeron C, Chin SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61(11):935\u201346.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"282_CR2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503. This article describes the clinical features and phenotypes of over 200 patients with pathologically-confirmed CBD and proposes new clinical research diagnostic criteria reflecting the identified phenotypes. While the criteria will require validation and revision, they are the first to incorporate CBD phenotypes other than just CBS","journal-title":"Neurology"},{"key":"282_CR3","first-page":"169","volume":"82","author":"KP Bhatia","year":"2000","unstructured":"Bhatia KP, Lee MS, Rinne JO, et al. Corticobasal degeneration look-alikes. Adv Neurol. 2000;82:169\u201382.","journal-title":"Adv Neurol"},{"issue":"4","key":"282_CR4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.53.4.795","volume":"53","author":"BF Boeve","year":"1999","unstructured":"Boeve BF, Maraganore DM, Parisi JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. 1999;53(4):795\u2013800.","journal-title":"Neurology"},{"issue":"1","key":"282_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/01.wnl.0000191307.69661.c3","volume":"66","author":"KA Josephs","year":"2006","unstructured":"Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66(1):41\u20138.","journal-title":"Neurology"},{"issue":"Pt 7","key":"282_CR6","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/brain\/awq123","volume":"133","author":"H Ling","year":"2010","unstructured":"Ling H, O'Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133(Pt 7):2045\u201357.","journal-title":"Brain"},{"issue":"1","key":"282_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1212\/WNL.48.1.119","volume":"48","author":"I Litvan","year":"1997","unstructured":"Litvan I, Agid Y, Goetz C, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48(1):119\u201325.","journal-title":"Neurology"},{"issue":"9","key":"282_CR8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.22574","volume":"24","author":"WT Hu","year":"2009","unstructured":"Hu WT, Rippon GW, Boeve BF, et al. Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord. 2009;24(9):1375\u20139.","journal-title":"Mov Disord"},{"issue":"11","key":"282_CR9","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/mds.22558","volume":"24","author":"BP Shelley","year":"2009","unstructured":"Shelley BP, Hodges JR, Kipps CM. Is the pathology of corticobasal syndrome predictable in life? Mov Disord. 2009;24(11):1593\u20139.","journal-title":"Mov Disord"},{"issue":"Pt 4","key":"282_CR10","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(Pt 4):861\u201370.","journal-title":"Brain"},{"issue":"21","key":"282_CR11","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1212\/WNL.0b013e3181feb2e8","volume":"75","author":"JL Whitwell","year":"2010","unstructured":"Whitwell JL, Jack Jr CR, Boeve BF, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology. 2010;75(21):1879\u201387.","journal-title":"Neurology"},{"issue":"2","key":"282_CR12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.22424","volume":"70","author":"SE Lee","year":"2011","unstructured":"Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327\u201340. This clinicopathological study describes clinical syndromes and imaging findings of patients with pathologically-proven CBD and also atrophy patterns of patients presenting with CBS. This is one of two recent imaging studies of patients with these conditions.","journal-title":"Ann Neurol"},{"issue":"16","key":"282_CR13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.wnl.0000259519.78480.c3","volume":"68","author":"R Murray","year":"2007","unstructured":"Murray R, Neumann M, Forman MS, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology. 2007;68(16):1274\u201383.","journal-title":"Neurology"},{"issue":"9","key":"282_CR14","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1212\/WNL.53.9.1969","volume":"53","author":"DA Grimes","year":"1999","unstructured":"Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology. 1999;53(9):1969\u201374.","journal-title":"Neurology"},{"key":"282_CR15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1385\/1-59259-834-X:309","volume-title":"Atypical Parkinsonian Disorders: Clinial and Research Aspects","author":"B Boeve","year":"2005","unstructured":"Boeve B. Corticobasal degeneration: the syndrome and the disease. In: Litvan I, editor. Atypical Parkinsonian Disorders: Clinial and Research Aspects. New Jersey: Humana Press; 2005. p. 309\u201334."},{"issue":"2","key":"282_CR16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.64.2.184","volume":"64","author":"GK Wenning","year":"1998","unstructured":"Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64(2):184\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"282_CR17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.55.7.957","volume":"55","author":"K Kompoliti","year":"1998","unstructured":"Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998;55(7):957\u201361.","journal-title":"Arch Neurol"},{"issue":"8","key":"282_CR18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1212\/WNL.40.8.1203","volume":"40","author":"DE Riley","year":"1990","unstructured":"Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology. 1990;40(8):1203\u201312.","journal-title":"Neurology"},{"issue":"2","key":"282_CR19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/1531-8257(200003)15:2<340::AID-MDS1025>3.0.CO;2-O","volume":"15","author":"S Frucht","year":"2000","unstructured":"Frucht S, Fahn S, Chin S, et al. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord. 2000;15(2):340\u20133.","journal-title":"Mov Disord"},{"issue":"5","key":"282_CR20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mds.1186","volume":"16","author":"C Cordivari","year":"2001","unstructured":"Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001;16(5):907\u201313.","journal-title":"Mov Disord"},{"issue":"2","key":"282_CR21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/mds.1038","volume":"16","author":"Z Vanek","year":"2001","unstructured":"Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord. 2001;16(2):252\u20137.","journal-title":"Mov Disord"},{"issue":"3","key":"282_CR22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s004150200009","volume":"249","author":"J M\u00fcller","year":"2002","unstructured":"M\u00fcller J, Wenning GK, Wissel J, et al. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol. 2002;249(3):300\u20134.","journal-title":"J Neurol"},{"key":"282_CR23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0072-9752(07)01249-3","volume":"89","author":"BF Boeve","year":"2008","unstructured":"Boeve BF, Josephs KA, Drubach DA. Current and future management of the corticobasal syndrome and corticobasal degeneration. Handb Clin Neurol. 2008;89:533\u201348.","journal-title":"Handb Clin Neurol."},{"issue":"12","key":"282_CR24","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00702-009-0301-2","volume":"116","author":"T Kov\u00e1cs","year":"2009","unstructured":"Kov\u00e1cs T, Farsang M, Vitaszil E, et al. Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases. J Neural Transm. 2009;116(12):1631\u20134.","journal-title":"J Neural Transm"},{"issue":"6","key":"282_CR25","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/mds.21970","volume":"23","author":"G Rossi","year":"2008","unstructured":"Rossi G, Marelli C, Farina L, et al. The G389R mutation in the MAPT gene presenting as sporadic corticobasal syndrome. Mov Disord. 2008;23(6):892\u20135.","journal-title":"Mov Disord"},{"issue":"8","key":"282_CR26","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/archneur.62.8.noc40425","volume":"62","author":"MS Okun","year":"2005","unstructured":"Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol. 2005;62(8):1250\u20135.","journal-title":"Arch Neurol"},{"issue":"8","key":"282_CR27","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.2522\/ptj.20060166","volume":"87","author":"TM Steffen","year":"2007","unstructured":"Steffen TM, Boeve BF, Mollinger-Riemann LA, Petersen CM. Long-term locomotor training for gait and balance in a patient with mixed progressive supranuclear palsy and corticobasal degeneration. Phys Ther. 2007;87(8):1078\u201387.","journal-title":"Phys Ther"},{"key":"282_CR28","doi-asserted-by":"crossref","unstructured":"Steffen TM, Boeve BF, Petersen CM, et al. Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year follow-up. Phys Ther. 2013;[Epub ahead of print].","DOI":"10.2522\/ptj.20130052"},{"issue":"Pt 7","key":"282_CR29","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/awq120","volume":"133","author":"S Hirano","year":"2010","unstructured":"Hirano S, Shinotoh H, Shimada H, et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain. 2010;133(Pt 7):2058\u201368.","journal-title":"Brain"},{"issue":"Suppl 3","key":"282_CR30","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26 Suppl 3:S42\u201380.","journal-title":"Mov Disord"},{"issue":"1","key":"282_CR31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","volume":"15","author":"MF Mendez","year":"2007","unstructured":"Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Amer J Geriatr Psychiatry. 2007;15(1):84\u20137.","journal-title":"Amer J Geriatr Psychiatry"},{"issue":"2","key":"282_CR32","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1447-0594.2012.00956.x","volume":"13","author":"T Kimura","year":"2013","unstructured":"Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int. 2013;13(2):506\u20137.","journal-title":"Geriatr Gerontol Int"},{"issue":"2","key":"282_CR33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","volume":"25","author":"A Kertesz","year":"2008","unstructured":"Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178\u201385.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"282_CR34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/gps.1973","volume":"23","author":"J Diehl-Schmid","year":"2008","unstructured":"Diehl-Schmid J, F\u00f6rstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23(7):754\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"282_CR35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","volume":"23","author":"M Vercelletto","year":"2011","unstructured":"Vercelletto M, Boutoleau-Bretonni\u00e8re C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23(4):749\u201359.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"282_CR36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/WAD.0b013e318197852f","volume":"23","author":"AL Boxer","year":"2009","unstructured":"Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 types of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23(3):211\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"282_CR37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","volume":"12","author":"AL Boxer","year":"2013","unstructured":"Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multi-centreer, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149\u201356.","journal-title":"Lancet Neurol"},{"issue":"3","key":"282_CR38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/WAD.0b013e3181cf468d","volume":"24","author":"NA Johnson","year":"2010","unstructured":"Johnson NA, Rademaker A, Weintraub S, et al. Pilot trial of memantine in primary progressive aphasia. Alzheimer Dis Assoc Disord. 2010;24(3):308.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"282_CR39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0033-3182(98)71313-1","volume":"39","author":"R Hargrave","year":"1998","unstructured":"Hargrave R, Rafal R. Depression in corticobasal degeneration. Psychosomatics. 1998;39(5):481\u20132.","journal-title":"Psychosomatics"},{"key":"282_CR40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000197896","volume":"24","author":"MF Mendez","year":"2009","unstructured":"Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009;24:168\u201378.","journal-title":"Front Neurol Neurosci."},{"issue":"6","key":"282_CR41","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/mds.20465","volume":"20","author":"MF Mendez","year":"2005","unstructured":"Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20(6):742\u20135.","journal-title":"Mov Disord"},{"issue":"1","key":"282_CR42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000067021","volume":"49","author":"R Moretti","year":"2003","unstructured":"Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13\u20139.","journal-title":"Eur Neurol"},{"issue":"3","key":"282_CR43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000076343","volume":"17","author":"M Ikeda","year":"2004","unstructured":"Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004;17(3):117\u201321.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"282_CR44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","volume":"20","author":"N Herrmann","year":"2012","unstructured":"Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20(9):789\u201397.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"282_CR45","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-003-1686-5","volume":"172","author":"JB Deakin","year":"2004","unstructured":"Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology. 2004;172(4):400\u20138.","journal-title":"Psychopharmacology"},{"issue":"4","key":"282_CR46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","volume":"17","author":"F Lebert","year":"2004","unstructured":"Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"282_CR47","volume":"4","author":"G Martinon-Torres","year":"2004","unstructured":"Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;4, CD004990.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20132","key":"282_CR48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1155\/2013\/824302","volume":"26","author":"ML Henry","year":"2013","unstructured":"Henry ML, Meese MV, Truong S, et al. Treatment for apraxia of speech in nonfluent variant primary progessive aphasia. Behav Neurol. 2013;26(1\u20132):77\u201388.","journal-title":"Behav Neurol"},{"issue":"1","key":"282_CR49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000341602","volume":"2","author":"L Farrajota","year":"2012","unstructured":"Farrajota L, Maruta C, Maroco J, et al. Speech therapy in primary progressive aphasia: a pilot study. Dement Geriatr Cogn Disord Extra. 2012;2(1):321\u201331.","journal-title":"Dement Geriatr Cogn Disord Extra"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0282-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-013-0282-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-013-0282-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T22:00:36Z","timestamp":1565128836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-013-0282-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,28]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s11940-013-0282-1","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,28]]},"article-number":"282"}}